Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

 
• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Nipah virus vaccine vial
A vaccine against Nipah virus is being developed by researchers from Oxford University in the UK (Shutterstock)

More from Review Pathways

More from R&D